ERBB2 and breast carcinoma: HER2+ breast cancer, which accounts for ~20% of all breast cancer cases, benefits from therapies targeting the epidermal growth factor 2 (ERBB2 or HER2/neu) gene, such as anti-ERBB2 antibodies and tyrosine kinase inhibitors (13).